There is some evidence, based on an initial meta-analysis of three Phase IV cardiovascular outcome trials [3], and further supported by a more recent narrative review [4] and an expanded meta-analysis of seven trials [5], that Asians with type 2 diabetes may have fewer major adverse cardiovascular events (MACE; nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) when treated with GLP-1 RAs than other racial groups. Here, GLP1R is linked to type 2 diabetes mellitus.